LONDON & BOULDER, Colorado – (COMMERCIAL THREAD) – Ixaka Ltd and SomaLogic today announce a research collaboration to support the development of bispecific aptamer-based therapies.
Collaboration to assess the safety and efficacy of antigen-specific SOMAmer® reagents (modified aptamers that bind tightly and specifically to target proteins) previously identified and screened by SomaLogic as potential candidates for combination with Ixaka’s anti-CD3 aptamers.
Ixaka is currently developing in vivo CAR-T therapies using its in vivo gene delivery technology, which facilitates in vivo targeting and transduction of the patient’s T cells. The universal in vivo The gene modification approach relies on proprietary anti-CD3 aptamers selected by Ixaka as targeting agents, which have been applied to the design of aptamer-based BiTEs (Bi-specific T-cell engagers).
SomaLogic’s antigen-specific SOMAmer reagents will now be evaluated with the aim of improving both the safety and efficacy of antibody-based bispecies. This follows a recent in vitro proof of concept study that successfully demonstrated the potential of Ixaka’s xCD3 cancer-specific antigen bispecific aptamers as novel anticancer agents capable of recruiting cytotoxic T cells and inducing tumor cell destruction.
Cécile Bauche, Vice-President and Scientific Director of Ixaka, said: “We have made great progress with our anti-CD3 aptamer candidate, with recent positive data demonstrating proof of concept in vitro when combined with a cancer-specific antigenic aptamer. SOMAmer molecules are a promising new class of drug entities with the potential to accelerate the development of our aptamer-based BiTEs as anticancer agents and help us in our mission to deliver new and effective cancer treatments. .
Renaud Vaillant, Vice-President, Business Development at Ixaka, commented: “We have been working with aptamers as potential immunotherapies since the inception of the company. We started chatting with SomaLogic 4 years ago, when the project was just an idea in a presentation. I am proud and excited to finally start this collaboration, which is the result of the tremendous work accomplished by our team. “
As part of this collaboration, SomaLogic will provide SOMAmères for the screening and subsequent evaluation of in vitro cytotoxic properties. Ixaka will lead the experiments to identify and assess SOMAmer candidates with high affinity and specificity. Further work will determine the operation in vitro properties of bispecific aptamers in human cell cultures and assess in vivo Anti-cancer efficacy in mouse models.
Nebojsa Janjic, Scientific Director of SomaLogic, commented: “The ability of SOMAmer reagents to bind with high specificity and affinity to any target protein makes them ideal for the development of new therapies in oncology. We hope to expand this collaboration with Ixaka in the future to support new treatments in other therapeutic areas.
SomaLogic’s anti-tumor SOMAmers demonstrate potential utility because the chemical addition of “protein-like” side chains to the nucleic acid bases that make up a SOMAmer can be used to develop molecules with high specificity and affinity for any one. targeted protein, which makes SOMAmer attractive candidates for new therapeutic development.
The first application of Ixaka’s TNP technology is the generation of CAR T therapies for hematologic malignancies. However, the modification of the components offers the potential to target a wide range of therapeutic cells for the treatment of many serious diseases, including cancers, genetic disorders, neurological and ocular diseases.
– ENDS –
Ixaka is a cell and gene therapy company focused on using the body’s natural powers to heal disease.
Ixaka’s proprietary technologies enhance the natural therapeutic power of cells by increasing the presence of healing cells at the disease site, or by directly modifying cells in the body to improve disease targeting and enhance their restorative effect.
Ixaka’s technologies – concentrated multicellular therapies and nanoparticulate therapies – demonstrate potential for the treatment of a wide range of serious diseases such as oncology, cardiovascular, neurological and ocular diseases and genetic disorders.
Ixaka has offices in London, UK, with R&D and manufacturing operations in Seville, Spain and Paris, France, as well as additional manufacturing capacity in Frankfurt, Germany.
For more information, please visit www.ixaka.com
SomaLogic seeks to provide accurate, meaningful and actionable health management information that enables individuals around the world to continuously optimize their personal health and well-being throughout their lives. This essential information, which must be provided through a global network of partners and users, is derived from SomaLogic’s precise, proprietary and personalized measurement of significant changes in an individual’s proteins over time. For more information visit www.somalogic.com and follow @somalogic on Twitter.